Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache

NCT04580238 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.

NCT NCT04580238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04580238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
Lead sponsor
University of Alberta
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2023
Completion date
June 30, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

botulinum toxins, type a, carotid dissection artery, cerebral venous sinus thrombosis, headache, migraine, hemorrhagic stroke, reversible cerebral vasoconstriction syndrome, stroke (cva) or tia, vertebral dissection artery